AbbVie Signs US$1.225 B Licensing Pact with IGI Therapeutics for Oncology and Autoimmune Disease Treatment
By Naini Anand
Pharma Deals Review: Vol 2025 Issue 8 (Table of Contents)
Published: 2 Aug-2025
DOI: 10.3833/pdr.v2025.i8.2964 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
IGI Therapeutics and AbbVie have entered into a global license agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT® (bispecific engagement by antibodies based on the T-cell receptor) protein platform, for oncology and autoimmune diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS